Jan Braune
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jan Braune has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Ulrich Keller
Department of Hematology, Oncology and Cancer Immunology Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt‐Universität Zu Berlin Berlin Germany
20 shared publications - Jan Krönke
Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany
19 shared publications - Francis Baumgartner
Charité - Universitätsmedizin Berlin, Berlin, Germany
17 shared publications - Matthias Wirth
Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany
17 shared publications - Philipp Mertins
Core Unit Proteomics, Berlin Institute of Health at Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany
17 shared publications - Amelie Gasper
Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Berlin, Germany
16 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data 4 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 4 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
MYC and KANSL2 co-regulated targets and their functions
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
MYC and KANSL2 co-regulated targets and their functions
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
KANSL2 influences the level of H3K27ac
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
KANSL2 influences the level of H3K27ac
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
MYC induces KANSL2 RNA and protein expression
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
MYC induces KANSL2 RNA and protein expression
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data 3 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
Supplementary Data 3 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 3 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
Supplementary Data 3 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
Supplementary Data 2 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
Supplementary Data 2 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
Panobinostat and OTX015 act synergistically in high KANSL2 MM cells
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
Panobinostat and OTX015 act synergistically in high KANSL2 MM cells
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
KANSL2 mRNA expression in MM cell lines
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
KANSL2 mRNA expression in MM cell lines
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
KANSL2 reshapes the transcriptomic and proteomic program of MM cells
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
KANSL2 reshapes the transcriptomic and proteomic program of MM cells
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma